NCT04639219: A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations

NCT04639219
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: HER2
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 120 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with clinically active central nervous system metastases
https://ClinicalTrials.gov/show/NCT04639219

Comments are closed.

Up ↑